Infant exposure to Fluvoxamine through placenta and human milk: a case series - A contribution from the ConcePTION project
IntroductionFluvoxamine is widely used to treat depression during pregnancy and lactation. However, limited data are available on its transfer to the fetus or in human milk. This case series provides additional information on the infant exposure to fluvoxamine during pregnancy and lactation.Case pre...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Psychiatry |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1167870/full |
| _version_ | 1797824117184921600 |
|---|---|
| author | Anaëlle Monfort Anaëlle Monfort Evelina Cardoso Chin B. Eap Chin B. Eap Chin B. Eap Chin B. Eap Céline J. Fischer Fumeaux Myriam Bickle Graz Mathilde Morisod Harari Etienne Weisskopf Peggy Gandia Karel Allegaert Karel Allegaert Karel Allegaert Karel Allegaert Hedvig Nordeng Hedvig Nordeng Jean-Michel Hascoët Olivier Claris Olivier Claris Manuella Epiney Chantal Csajka Chantal Csajka Chantal Csajka Monia Guidi Monia Guidi Ema Ferreira Ema Ferreira Alice Panchaud Alice Panchaud |
| author_facet | Anaëlle Monfort Anaëlle Monfort Evelina Cardoso Chin B. Eap Chin B. Eap Chin B. Eap Chin B. Eap Céline J. Fischer Fumeaux Myriam Bickle Graz Mathilde Morisod Harari Etienne Weisskopf Peggy Gandia Karel Allegaert Karel Allegaert Karel Allegaert Karel Allegaert Hedvig Nordeng Hedvig Nordeng Jean-Michel Hascoët Olivier Claris Olivier Claris Manuella Epiney Chantal Csajka Chantal Csajka Chantal Csajka Monia Guidi Monia Guidi Ema Ferreira Ema Ferreira Alice Panchaud Alice Panchaud |
| author_sort | Anaëlle Monfort |
| collection | DOAJ |
| description | IntroductionFluvoxamine is widely used to treat depression during pregnancy and lactation. However, limited data are available on its transfer to the fetus or in human milk. This case series provides additional information on the infant exposure to fluvoxamine during pregnancy and lactation.Case presentationTwo women, aged 38 and 34 years, diagnosed with depression were treated with 50 mg fluvoxamine during pregnancy and lactation. At delivery a paired maternal and cord blood sample was collected for each woman. The first mother exclusively breastfed her child for 4 months and gave one foremilk and one hindmilk sample at 2 days and 4 weeks post-partum, whereas the second mother did not breastfeed.ResultsThe cord to plasma concentration ratios were 0.62 and 0.48, respectively. At 2 weeks post-partum, relative infant doses (RID) were 0.47 and 0.57% based on fluvoxamine concentrations in foremilk and hindmilk, respectively. At 4 weeks post-partum, the RIDs were 0.35 and 0.90%, respectively. The child from the first mother was born healthy and showed a normal development at the 6th, 18th and 36th month follow-ups. One of the twins from the second woman was hospitalized for hypoglycemia that was attributed to gestational diabetes and low birth weight. The second one was born healthy.ConclusionThese results suggest a minimal exposure to fluvoxamine during lactation which is in accordance with previously published data. Larger clinical and pharmacokinetic studies assessing the long-term safety of this drug during lactation and the variability of its exposure through breastmilk are warranted. |
| first_indexed | 2024-03-13T10:34:13Z |
| format | Article |
| id | doaj.art-9f9c1db79b0247a78d95dda076c41324 |
| institution | Directory Open Access Journal |
| issn | 1664-0640 |
| language | English |
| last_indexed | 2024-03-13T10:34:13Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Psychiatry |
| spelling | doaj.art-9f9c1db79b0247a78d95dda076c413242023-05-18T08:06:17ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402023-05-011410.3389/fpsyt.2023.11678701167870Infant exposure to Fluvoxamine through placenta and human milk: a case series - A contribution from the ConcePTION projectAnaëlle Monfort0Anaëlle Monfort1Evelina Cardoso2Chin B. Eap3Chin B. Eap4Chin B. Eap5Chin B. Eap6Céline J. Fischer Fumeaux7Myriam Bickle Graz8Mathilde Morisod Harari9Etienne Weisskopf10Peggy Gandia11Karel Allegaert12Karel Allegaert13Karel Allegaert14Karel Allegaert15Hedvig Nordeng16Hedvig Nordeng17Jean-Michel Hascoët18Olivier Claris19Olivier Claris20Manuella Epiney21Chantal Csajka22Chantal Csajka23Chantal Csajka24Monia Guidi25Monia Guidi26Ema Ferreira27Ema Ferreira28Alice Panchaud29Alice Panchaud30CHU Sainte-Justine, Montréal, QC, CanadaFaculty of Pharmacy, Université de Montréal, Montréal, QC, CanadaService of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, SwitzerlandCenter for Research and Innovation in Clinical Pharmaceutical Sciences, University Hospital and University of Lausanne, Lausanne, SwitzerlandSchool of Pharmaceutical Sciences, University of Geneva, Geneva, SwitzerlandInstitute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, SwitzerlandUnit of Pharmacogenetics and Clinical Psychopharmacology, Department of Psychiatry, Lausanne University Hospital, Lausanne, SwitzerlandClinic of Neonatology, Department Mother-Woman-Child, Lausanne University Hospital, Lausanne, SwitzerlandClinic of Neonatology, Department Mother-Woman-Child, Lausanne University Hospital, Lausanne, SwitzerlandDivision of Child and Adolescent Psychiatry, Lausanne University Hospital, Lausanne, SwitzerlandCenter for Research and Innovation in Clinical Pharmaceutical Sciences, University Hospital and University of Lausanne, Lausanne, Switzerland0Laboratory of Pharmacokinetics and Toxicology, Purpan Hospital, University Hospital of Toulouse, Toulouse, France1Child and Youth Institute, KU Leuven, Leuven, Belgium2Department of Development and Regeneration, KU Leuven, Leuven, Belgium3Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium4Department of Hospital Pharmacy, Erasmus MC, Rotterdam, Netherlands5Pharmacoepidemiology and Drug Safety Research Group, Department of Pharmacy, PharmaTox Strategic Initiative, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway6Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway7Department of Neonatology, Maternité Régionale, Université de Lorraine, Nancy, France8Department of Neonatology, Hospices Civils de Lyon, Lyon, France9Claude Bernard University, P2S 4129, Lyon, France0Department of Women, Child and Adolescent, Geneva University Hospital, Geneva, SwitzerlandCenter for Research and Innovation in Clinical Pharmaceutical Sciences, University Hospital and University of Lausanne, Lausanne, SwitzerlandSchool of Pharmaceutical Sciences, University of Geneva, Geneva, SwitzerlandInstitute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, SwitzerlandCenter for Research and Innovation in Clinical Pharmaceutical Sciences, University Hospital and University of Lausanne, Lausanne, Switzerland1Service of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, SwitzerlandCHU Sainte-Justine, Montréal, QC, CanadaFaculty of Pharmacy, Université de Montréal, Montréal, QC, CanadaService of Pharmacy, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland2Institute of Primary Health Care (BIHAM), University of Bern, Bern, SwitzerlandIntroductionFluvoxamine is widely used to treat depression during pregnancy and lactation. However, limited data are available on its transfer to the fetus or in human milk. This case series provides additional information on the infant exposure to fluvoxamine during pregnancy and lactation.Case presentationTwo women, aged 38 and 34 years, diagnosed with depression were treated with 50 mg fluvoxamine during pregnancy and lactation. At delivery a paired maternal and cord blood sample was collected for each woman. The first mother exclusively breastfed her child for 4 months and gave one foremilk and one hindmilk sample at 2 days and 4 weeks post-partum, whereas the second mother did not breastfeed.ResultsThe cord to plasma concentration ratios were 0.62 and 0.48, respectively. At 2 weeks post-partum, relative infant doses (RID) were 0.47 and 0.57% based on fluvoxamine concentrations in foremilk and hindmilk, respectively. At 4 weeks post-partum, the RIDs were 0.35 and 0.90%, respectively. The child from the first mother was born healthy and showed a normal development at the 6th, 18th and 36th month follow-ups. One of the twins from the second woman was hospitalized for hypoglycemia that was attributed to gestational diabetes and low birth weight. The second one was born healthy.ConclusionThese results suggest a minimal exposure to fluvoxamine during lactation which is in accordance with previously published data. Larger clinical and pharmacokinetic studies assessing the long-term safety of this drug during lactation and the variability of its exposure through breastmilk are warranted.https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1167870/fullfluvoxamineinfant exposurehuman milkcord bloodlactationpregnancy |
| spellingShingle | Anaëlle Monfort Anaëlle Monfort Evelina Cardoso Chin B. Eap Chin B. Eap Chin B. Eap Chin B. Eap Céline J. Fischer Fumeaux Myriam Bickle Graz Mathilde Morisod Harari Etienne Weisskopf Peggy Gandia Karel Allegaert Karel Allegaert Karel Allegaert Karel Allegaert Hedvig Nordeng Hedvig Nordeng Jean-Michel Hascoët Olivier Claris Olivier Claris Manuella Epiney Chantal Csajka Chantal Csajka Chantal Csajka Monia Guidi Monia Guidi Ema Ferreira Ema Ferreira Alice Panchaud Alice Panchaud Infant exposure to Fluvoxamine through placenta and human milk: a case series - A contribution from the ConcePTION project Frontiers in Psychiatry fluvoxamine infant exposure human milk cord blood lactation pregnancy |
| title | Infant exposure to Fluvoxamine through placenta and human milk: a case series - A contribution from the ConcePTION project |
| title_full | Infant exposure to Fluvoxamine through placenta and human milk: a case series - A contribution from the ConcePTION project |
| title_fullStr | Infant exposure to Fluvoxamine through placenta and human milk: a case series - A contribution from the ConcePTION project |
| title_full_unstemmed | Infant exposure to Fluvoxamine through placenta and human milk: a case series - A contribution from the ConcePTION project |
| title_short | Infant exposure to Fluvoxamine through placenta and human milk: a case series - A contribution from the ConcePTION project |
| title_sort | infant exposure to fluvoxamine through placenta and human milk a case series a contribution from the conception project |
| topic | fluvoxamine infant exposure human milk cord blood lactation pregnancy |
| url | https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1167870/full |
| work_keys_str_mv | AT anaellemonfort infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT anaellemonfort infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT evelinacardoso infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT chinbeap infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT chinbeap infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT chinbeap infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT chinbeap infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT celinejfischerfumeaux infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT myriambicklegraz infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT mathildemorisodharari infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT etienneweisskopf infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT peggygandia infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT karelallegaert infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT karelallegaert infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT karelallegaert infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT karelallegaert infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT hedvignordeng infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT hedvignordeng infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT jeanmichelhascoet infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT olivierclaris infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT olivierclaris infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT manuellaepiney infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT chantalcsajka infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT chantalcsajka infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT chantalcsajka infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT moniaguidi infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT moniaguidi infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT emaferreira infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT emaferreira infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT alicepanchaud infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject AT alicepanchaud infantexposuretofluvoxaminethroughplacentaandhumanmilkacaseseriesacontributionfromtheconceptionproject |